Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias
- PMID: 28131410
- DOI: 10.1016/j.rec.2017.01.001
Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias
Erratum in
-
Correction in article "Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias", Rev Esp Cardiol. 2017;70:72-77.Rev Esp Cardiol (Engl Ed). 2018 Jun;71(6):509-510. doi: 10.1016/j.rec.2018.03.015. Epub 2018 May 1. Rev Esp Cardiol (Engl Ed). 2018. PMID: 29724636 English, Spanish. No abstract available.
Comment on
-
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1. Atherosclerosis. 2016. PMID: 27594540 No abstract available.
Similar articles
-
[A perspective to lipid lowering therapy after ESC/EAS guidelines for the management of dyslipidaemias and the European guidelines on cardiovascular disease prevention in clinical practice].Turk Kardiyol Dern Ars. 2012 Jun;40(4):293-7. doi: 10.5543/tkda.2012.83873. Turk Kardiyol Dern Ars. 2012. PMID: 22951844 Turkish. No abstract available.
-
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Atherosclerosis. 2011 Jul;217 Suppl 1:S1-44. doi: 10.1016/j.atherosclerosis.2011.06.012. Atherosclerosis. 2011. PMID: 21723445 Review. No abstract available.
-
Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias.Rev Esp Cardiol (Engl Ed). 2020 May;73(5):348-353. doi: 10.1016/j.rec.2019.11.019. Epub 2020 Mar 21. Rev Esp Cardiol (Engl Ed). 2020. PMID: 32205101 English, Spanish. No abstract available.
-
How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.Curr Med Res Opin. 2015 Feb;31(2):221-8. doi: 10.1185/03007995.2014.982751. Epub 2014 Nov 24. Curr Med Res Opin. 2015. PMID: 25418708
-
[New guidelines on dyslipidemia management: Comparison of French (HAS) and European (ESC/EAS) guidelines].Presse Med. 2018 Sep;47(9):769-774. doi: 10.1016/j.lpm.2018.09.002. Epub 2018 Sep 28. Presse Med. 2018. PMID: 30274915 Review. French.
Cited by
-
Effects of Two Community-Based Exercise Programs on Adherence, Cardiometabolic Markers, and Body Composition in Older People with Cardiovascular Risk Factors: A Prospective Observational Cohort Study.J Pers Med. 2020 Oct 16;10(4):176. doi: 10.3390/jpm10040176. J Pers Med. 2020. PMID: 33081361 Free PMC article.
-
Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe (-/-) mice.Acta Pharm Sin B. 2020 Sep;10(9):1769-1783. doi: 10.1016/j.apsb.2020.03.005. Epub 2020 Apr 8. Acta Pharm Sin B. 2020. PMID: 33088695 Free PMC article.
-
Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients.Cardiol Res Pract. 2022 Sep 10;2022:9464733. doi: 10.1155/2022/9464733. eCollection 2022. Cardiol Res Pract. 2022. PMID: 36124294 Free PMC article.
-
Leonurine: a comprehensive review of pharmacokinetics, pharmacodynamics, and toxicology.Front Pharmacol. 2024 Jul 19;15:1428406. doi: 10.3389/fphar.2024.1428406. eCollection 2024. Front Pharmacol. 2024. PMID: 39101131 Free PMC article. Review.
-
Anti-hypercholesterolemic Effects and a Good Safety Profile of SCM-198 in Animals: From ApoE Knockout Mice to Rhesus Monkeys.Front Pharmacol. 2018 Dec 13;9:1468. doi: 10.3389/fphar.2018.01468. eCollection 2018. Front Pharmacol. 2018. PMID: 30618759 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources